Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases

Understanding the risk factors for breakthrough coronavirus disease 2019 (COVID-19) (BC19) is critical to inform policy. Herein, we assessed Delta (Lineage B.1.617.2) variant-specific effectiveness of the BNT162b2 (Pfizer) vaccine and characterized Delta-driven BC19 cases (fully vaccinated individua...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, Luan D, Wallace, Shonta, Phan, Anh TQ, Christofferson, Rebecca C, Turner, Erik, Parker, Sean, Elkind-Hirsch, Karen, Landry, Darrell, Stansbury, Austin, Rose, Rebecca, Nolan, David J, Lamers, Susanna L, Hirezi, Michael, Ogden, Beverly, Cormier, Stephania A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679329/
https://www.ncbi.nlm.nih.gov/pubmed/36408542
http://dx.doi.org/10.1177/15353702221134097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679329/
https://www.ncbi.nlm.nih.gov/pubmed/36408542
http://dx.doi.org/10.1177/15353702221134097

Ejemplares similares